News Intercept's Ocaliva approved in EU for liver disease Potential liver blockbuster gets EU licence.
News EU regulator recommends Intercept's potential liver blockbus... Sales forecast to reach $2.6 billion in 2020.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.